Athenex (ATNX) PT Lowered to $13 at Laidlaw, Following FDA CRL, Earnings

March 1, 2021 1:56 PM EST
Get Alerts ATNX Hot Sheet
Price: $3.98 -3.4%

Rating Summary:
    8 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Laidlaw analyst Yale Jen lowered the price target on Athenex (NASDAQ: ATNX) to $13.00 (from $38.00) while maintaining a Buy rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities

Earnings, FDA